BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32036492)

  • 1. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
    Nakajima TE; Yamaguchi K; Boku N; Hyodo I; Mizusawa J; Hara H; Nishina T; Sakamoto T; Shitara K; Shinozaki K; Katayama H; Nakamura S; Muro K; Terashima M
    Gastric Cancer; 2020 Jul; 23(4):677-688. PubMed ID: 32036492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
    Arai H; Inoue E; Yamaguchi K; Boku N; Hara H; Nishina T; Tsuda M; Shitara K; Shinozaki K; Nakamura S; Hyodo I; Muro K; Sasako M; Terashima M; Nakajima TE
    Cancer Med; 2021 Nov; 10(21):7673-7682. PubMed ID: 34655175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
    Iwasa S; Goto M; Yasui H; Nishina T; Takahari D; Nakayama N; Taira K; Kusaba H; Fuse N; Hironaka S; Shimada Y; Nakajima TE
    Jpn J Clin Oncol; 2012 Sep; 42(9):787-93. PubMed ID: 22782960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
    Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
    Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake.
    Hara H; Kadowaki S; Asayama M; Ooki A; Yamada T; Yoshii T; Yamaguchi K
    Int J Clin Oncol; 2018 Apr; 23(2):275-280. PubMed ID: 29039072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer].
    Kawada J; Nishino M; Hosoda Y; Hoshino H; Okano M; Nagai K; Okuyama M; Kim Y; Tsujinaka T
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1951-1953. PubMed ID: 28133186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases.
    Masuishi T; Nakajima TE; Yamazaki K; Hironaka S; Kudo C; Yoshimura K; Muro K
    Future Oncol; 2020 Jul; 16(20):1417-1424. PubMed ID: 32466683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapeutic Strategies for Peritoneal Dissemination of Gastric Cancer].
    Matsushima T; Wakatsuki T; Takahari D; Chin K; Yamaguchi K
    Gan To Kagaku Ryoho; 2016 Dec; 43(13):2477-2480. PubMed ID: 28028252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
    Moehler M; Eimermacher A; Siebler J; Höhler T; Wein A; Menges M; Flieger D; Junginger T; Geer T; Gracien E; Galle PR; Heike M
    Br J Cancer; 2005 Jun; 92(12):2122-8. PubMed ID: 15942629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer.
    Iwasa S; Nakajima TE; Nakamura K; Takashima A; Kato K; Hamaguchi T; Yamada Y; Shimada Y
    Gastric Cancer; 2012 Jan; 15(1):21-6. PubMed ID: 21573919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
    Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
    Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
    Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Kato K; Nagai Y; Iwasa S; Nakajima TE; Hamaguchi T; Yamada Y; Takagi S; Kobayashi K; Yoshioka A; Nakayama N; Tsuji A
    Oncology; 2011; 81(5-6):291-7. PubMed ID: 22134040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
    Fuchs CS; Niedzwiecki D; Mamon HJ; Tepper JE; Ye X; Swanson RS; Enzinger PC; Haller DG; Dragovich T; Alberts SR; Bjarnason GA; Willett CG; Gunderson LL; Goldberg RM; Venook AP; Ilson D; O'Reilly E; Ciombor K; Berg DJ; Meyerhardt J; Mayer RJ
    J Clin Oncol; 2017 Nov; 35(32):3671-3677. PubMed ID: 28976791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.